Harmony Biosciences’ (HRMY) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $55.00 price target on the stock. HC Wainwright also issued estimates for Harmony Biosciences’ Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $1.09 EPS, Q4 2026 earnings at $1.31 EPS and FY2030 earnings at $7.07 EPS.

Several other equities analysts have also commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. Zacks Research upgraded Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. UBS Group lowered Harmony Biosciences from a “buy” rating to a “neutral” rating and increased their target price for the stock from $43.00 to $46.00 in a research report on Wednesday, February 11th. Needham & Company LLC cut their target price on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Bank of America reduced their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $42.67.

Harmony Biosciences Stock Performance

HRMY stock opened at $28.54 on Wednesday. The stock’s 50 day simple moving average is $36.01 and its 200 day simple moving average is $34.07. Harmony Biosciences has a 12-month low of $25.52 and a 12-month high of $40.87. The firm has a market cap of $1.65 billion, a P/E ratio of 10.53, a P/E/G ratio of 0.36 and a beta of 0.84. The company has a current ratio of 3.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.17.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, February 24th. The company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). The business had revenue of $243.78 million during the quarter, compared to analyst estimates of $240.04 million. Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 EPS. As a group, equities research analysts predict that Harmony Biosciences will post 2.43 EPS for the current year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 3,746 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the sale, the chief financial officer directly owned 24,521 shares in the company, valued at $910,955.15. This represents a 13.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 50,640 shares of company stock worth $1,932,256. 23.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Harmony Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Amundi lifted its holdings in Harmony Biosciences by 115.6% in the 1st quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after acquiring an additional 21,266 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after purchasing an additional 984 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Harmony Biosciences in the 1st quarter worth approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Harmony Biosciences by 53.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after purchasing an additional 33,058 shares during the last quarter. Finally, AlphaQuest LLC boosted its holdings in Harmony Biosciences by 340.2% during the second quarter. AlphaQuest LLC now owns 17,601 shares of the company’s stock worth $556,000 after buying an additional 13,603 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences News Summary

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $55 price target and published a long-range FY2030 EPS projection (which reinforces an upbeat long-term thesis), supporting upside potential despite near-term cuts. HC Wainwright research on HRMY
• Neutral Sentiment: An aggregate coverage note reported HRMY has an average analyst rating of “Moderate Buy,” indicating mixed consensus sentiment across the sell-side. This tempers the impact of individual downgrades but leaves the stock sensitive to further model changes. Average analyst rating report
• Negative Sentiment: Zacks Research downgraded HRMY from “strong-buy” to “hold,” reducing near-term buy-side conviction and likely contributing to selling pressure. Zacks downgrade
• Negative Sentiment: Truist Securities downgraded HRMY to “Hold” citing patent trial developments — a direct legal/intellectual property risk that can materially affect exclusivity and future revenue, and is a key reason for today’s weakness. Truist downgrade after patent trial developments
• Negative Sentiment: HC Wainwright also lowered near-term EPS forecasts across Q1–Q4 2026 (multiple cuts to quarterly estimates), signaling weaker near-term profitability expectations that can pressure the stock until guidance or sales trends rebound. HC Wainwright EPS revision details

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.